This site uses cookies to provide a better browsing experience. More information can be found on our Privacy Policy page.

NodThera has changed its name to Rezera and announced a Phase 3 development program. Read Press Release

Newsroom

Stay informed on our latest company updates, scientific advancements, clinical milestones, and corporate announcements as we continue advancing NLRP3-based medicines.

Media Article

NodThera’s NLRP3 inhibitor shows further anti-inflammatory promise in phase 1b/2a obesity trial

Fierce Biotech
Media Article

NodThera’s NT-0796 Shows Promise as Parkinson Disease Treatment in Phase 1b/2a Trial

Neurology Live
Media Article

NT-0796 shows sustained easing of inflammation in Phase 1/2 trial

Parkinson’s News Today

Join Our Team